Iterum Therapeutics plc
ITRM
$0.6833
-$0.0377-5.23%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -33.08% | 25.69% | -8.01% | -21.95% | 29.63% |
Total Depreciation and Amortization | 0.57% | 33.72% | 3,162.50% | 0.00% | 14.29% |
Total Amortization of Deferred Charges | -100.00% | 113.84% | -154.94% | 348.51% | 0.00% |
Total Other Non-Cash Items | 1.54% | -68.20% | 422.67% | -18.05% | -4.92% |
Change in Net Operating Assets | 35.71% | 81.27% | -1,845.21% | 97.90% | 55.14% |
Cash from Operations | -55.26% | 28.10% | -59.28% | 60.47% | 48.34% |
Capital Expenditure | 100.00% | -- | -- | 100.00% | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -80.70% | 35.75% | -41.77% |
Cash from Investing | 100.00% | -100.18% | -80.70% | 35.81% | -41.80% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | 100.00% | -- | -- | -- | -- |
Issuance of Common Stock | -19.46% | -54.19% | 155.56% | 3,151.50% | -97.69% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 161.04% | -160.45% | 155.56% | 3,151.50% | -97.69% |
Foreign Exchange rate Adjustments | 121.74% | -1,050.00% | 92.86% | -55.56% | 33.33% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 103.26% | -207.03% | 27.15% | 449.36% | -283.08% |